Literature DB >> 31152546

PD-L1 Expression Patterns in Microsatellite Instability-High Intestinal Adenocarcinoma Subtypes.

Jordan Roberts1, Safia N Salaria1, Justin Cates1, Yang Wang1, Cindy Vnencak-Jones1, Jordan Berlin2, Chanjuan Shi1.   

Abstract

OBJECTIVES: To investigate patterns of programmed death protein-1 (PD-L1) expression in microsatellite instability (MSI)-high intestinal carcinomas and correlate them with pathologic and molecular features.
METHODS: One hundred and fifteen MSI-high and 41 microsatellite stable carcinomas were included. Tumor sections were immunohistochemically labeled for PD-L1. The results were correlated with histologic subtypes, MSI, and BRAF status.
RESULTS: As expected, MSI status was associated with PD-L1 expression. Among 115 MSI-high tumors, PD-L1 expression was observed on tumor cells in 28 tumors and on tumor-associated inflammatory cells in 77 tumors. Medullary carcinoma demonstrated more frequent PD-L1 expression on tumor cells than mucinous and typical adenocarcinoma. PD-L1 expression was more frequent in medullary and typical adenocarcinoma than in mucinous adenocarcinoma based on combined positive scores. Tumors with more nucleotide shifts by PCR-based MSI testing were more likely to express PD-L1.
CONCLUSIONS: Expression of PD-L1 is different among different histologic subtypes of MSI-high intestinal carcinomas. © American Society for Clinical Pathology, 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Histologic subtypes; Intestinal carcinoma; MSI-high; PD-L1

Year:  2019        PMID: 31152546      PMCID: PMC6669412          DOI: 10.1093/ajcp/aqz052

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  22 in total

1.  PD-L1 Testing in Cancer: Challenges in Companion Diagnostic Development.

Authors:  Aaron R Hansen; Lillian L Siu
Journal:  JAMA Oncol       Date:  2016-01       Impact factor: 31.777

2.  Histopathological identification of colon cancer with microsatellite instability.

Authors:  J Alexander; T Watanabe; T T Wu; A Rashid; S Li; S R Hamilton
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

3.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

Authors:  Dung T Le; Jennifer N Uram; Hao Wang; Bjarne R Bartlett; Holly Kemberling; Aleksandra D Eyring; Andrew D Skora; Brandon S Luber; Nilofer S Azad; Dan Laheru; Barbara Biedrzycki; Ross C Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Steven M Duffy; Richard M Goldberg; Albert de la Chapelle; Minori Koshiji; Feriyl Bhaijee; Thomas Huebner; Ralph H Hruban; Laura D Wood; Nathan Cuka; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; Shibin Zhou; Toby C Cornish; Janis M Taube; Robert A Anders; James R Eshleman; Bert Vogelstein; Luis A Diaz
Journal:  N Engl J Med       Date:  2015-05-30       Impact factor: 91.245

4.  The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints.

Authors:  Nicolas J Llosa; Michael Cruise; Ada Tam; Elizabeth C Wicks; Elizabeth M Hechenbleikner; Janis M Taube; Richard L Blosser; Hongni Fan; Hao Wang; Brandon S Luber; Ming Zhang; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Cynthia L Sears; Robert A Anders; Drew M Pardoll; Franck Housseau
Journal:  Cancer Discov       Date:  2014-10-30       Impact factor: 39.397

5.  PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes.

Authors:  Matthew W Rosenbaum; Jacob R Bledsoe; Vicente Morales-Oyarvide; Tiffany G Huynh; Mari Mino-Kenudson
Journal:  Mod Pathol       Date:  2016-05-20       Impact factor: 7.842

6.  Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.

Authors:  Haidong Dong; Scott E Strome; Diva R Salomao; Hideto Tamura; Fumiya Hirano; Dallas B Flies; Patrick C Roche; Jun Lu; Gefeng Zhu; Koji Tamada; Vanda A Lennon; Esteban Celis; Lieping Chen
Journal:  Nat Med       Date:  2002-06-24       Impact factor: 53.440

Review 7.  Microsatellite Instability as a Biomarker for PD-1 Blockade.

Authors:  Jonathan C Dudley; Ming-Tseh Lin; Dung T Le; James R Eshleman
Journal:  Clin Cancer Res       Date:  2016-02-15       Impact factor: 12.531

8.  Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.

Authors:  Yoshiko Iwai; Masayoshi Ishida; Yoshimasa Tanaka; Taku Okazaki; Tasuku Honjo; Nagahiro Minato
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-06       Impact factor: 11.205

9.  Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1.

Authors:  Daniel S Chen; Bryan A Irving; F Stephen Hodi
Journal:  Clin Cancer Res       Date:  2012-10-19       Impact factor: 12.531

10.  Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens.

Authors:  Marina K Baine; Gabriela Turcu; Christopher R Zito; Adebowale J Adeniran; Robert L Camp; Lieping Chen; Harriet M Kluger; Lucia B Jilaveanu
Journal:  Oncotarget       Date:  2015-09-22
View more
  2 in total

1.  IFNγ/PD-L1 Signaling Improves the Responsiveness of Anti-PD-1 Therapy in Colorectal Cancer: An in vitro Study.

Authors:  Wenli Yuan; Deyao Deng; Hanyu Li; Xinghui Hu; Xueqin Shang; Xia Hou; Hongchao Jiang; Hongchun He
Journal:  Onco Targets Ther       Date:  2021-05-07       Impact factor: 4.147

Review 2.  Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies.

Authors:  Alberto Puccini; Francesca Battaglin; Maria Laura Iaia; Heinz-Josef Lenz; Mohamed E Salem
Journal:  J Immunother Cancer       Date:  2020-05       Impact factor: 13.751

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.